Effectiveness of Combined GLP-1 Receptor Agonist Therapy and Structured Exercise on Skeletal Muscle Morphology, Quality, and Physical Function in Overweight and Obese Individuals

NCT07609160 · Not yet recruiting

Last updated 2026-05-28

This clinical trial tests whether a combination of a GLP-1 receptor agonist and structured exercise improves muscle health and function in adults who are overweight or obese.

Status Not yet recruiting Approved but enrollment has not started.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, single-blind treatment study

Participants 108 people Planned (estimated).

Who can join Ages 18–65 · all sexes

Timeline Started 2026-11 · est. completion 2028-01

What this study is testing ClinicalTrials.gov NCT07609160 ↗

Description as written by the study sponsor.

This randomized controlled trial aims to investigate the effects of a 24-week home-based progressive resistance exercise program combined with tirzepatide treatment on skeletal muscle mass, muscle quality, and functional capacity in overweight and obese individuals. A total of 108 participants initiating tirzepatide therapy will be randomized to either exercise plus pharmacotherapy or pharmacotherapy alone. The primary outcome is change in thigh muscle thickness and echo intensity assessed by ultrasonography.

Treatments tested

Resistance exercise Other

A 24-week home-based resistance exercises using elastic band and bodyweight
Lifestyle recommendations Other

Lifestyle recommendations including physical activity and nutritional advice

Main thing measured	Change in muscle thickness
Sponsor	Acibadem University
Conditions studied	Obesity, Sarcopenia, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07609160 ↗